989 East Hillsdale Blvd.
Tel: (650) 209-4055
About Apollomics, Inc.
Apollomics, Inc. is an innovative biopharmaceutical company committed to bridging innovation from East and West to discover and develop oncology combination therapies that harness the immune system and target specific molecular pathways to defeat cancer globally. Apollomics’ existing pipeline consists of development-stage assets including novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. At Apollomics, we are a purpose driven company imagining a world without cancer. We let science drive our decision making to advance our programs. We believe in the power of partnerships to enhance our pipeline and broaden the patient populations we serve.
61 articles about Apollomics, Inc.
Apollomics Inc. today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will present virtually at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024 at 10:40 a.m. ET.
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement
Apollomics Inc. announced that on January 16, 2024, it received a notification from The Nasdaq Stock Market LLC stating that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550, because the closing bid price of the Company’s Class A ordinary shares, par value $0.0001 per share, was below $1.00 per share for 30 consecutive business days.
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Apollomics Inc. announced the completion of enrollment in its Phase 3 bridging study evaluating uproleselan, an investigational, first-in-class E-selectin antagonist, added to a standard chemotherapy regimen for the treatment of adults with relapsed or refractory acute myeloid leukemia.
Apollomics Inc. announced that Sanjeev Redkar, Ph.D., Co-Founder and President, will present at the 2024 Biotech Showcase on Monday, January 8, 2024 at 10:30 a.m. PT at the Hilton San Francisco Union Square in San Francisco, Calif.
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
Apollomics Inc. today announced the presentation of vebreltinib efficacy and safety data from the ongoing multi-cohort Phase 2 KUNPENG trial (NCT04258033) and the ongoing global multi-cohort Phase 2 SPARTA trial (NCT03175224) at the 2023 IASLC North America Conference on Lung Cancer (NACLC), that was held December 1-3, 2023, in Chicago, Illinois.
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
Apollomics Inc. today announced that Guo-Liang Yu, Ph.D., Co-Founder and Chief Executive Officer of Apollomics and Sanjeev Redkar, Ph.D., Co-Founder and President, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023 at 11:30 a.m. ET.
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
Apollomics Inc. today announced that its partner in China, Avistone Biotechnology Co. Ltd., received conditional approval from the National Medical Products Administration (NMPA) of China for the commercialization of vebreltinib to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC).
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
Apollomics Inc. today announced the addition of two new cohorts in its ongoing global multi-cohort Phase 2 SPARTA study (NCT03175224), which is evaluating vebreltinib (APL-101) in patients with non-small cell lung cancer (NSCLC) and other solid tumors.
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
Apollomics Inc., announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Medical Oncology Congress 2023, being held in Madrid, Spain from October 20-24, 2023.
Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
Apollomics Inc. announced that the company’s Co-Founder and President, Sanjeev Redkar, MBA, Ph.D., will speak at the 23rd Annual R. Bryan Miller Symposium, an event exploring the interface of chemical biology and organic chemistry in honor of Professor R. Bryan Miller, at the University of California, Davis on April 14, 2023.
On March 30, 2023, Apollomics Inc., an innovative biopharmaceutical company and portfolio company of Qiming Venture Partners, listed on Nasdaq through a SPAC merger with Maxpro Capital Acquisition Corp.
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq
Apollomics Inc., a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced the completion of its business combination with Maxpro Capital Acquisition Corp.
Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations
Apollomics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to vebreltinib (APL-101) for the treatment of non-small cell lung cancer (NSCLC) with MET genomic tumor aberrations.
Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.
Apollomics Inc., a late-stage clinical biopharmaceutical company, and Maxpro Capital Acquisition Corp. announced a definitive agreement for a business combination that would result in Apollomics becoming a publicly traded company on the Nasdaq Global Market.
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer
Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief Scientific Officer.
1/7/2022With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers.
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
Apollomics Inc. today announced that Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer of Apollomics, was recently appointed to Chairman of the Board for the BayHelix Group, effective January 2022.
11/29/2021Thanksgiving week was marked by numerous clinical trial announcements. Here’s a look.
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Apollomics Inc. today announced that the first patient has been successfully dosed in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China.
It was a busy week for clinical trial news. Here’s a look.